BHCM
GILD icon

Brevan Howard Capital Management’s Gilead Sciences GILD Stock Holding History

Brevan Howard Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Buy
123,329
+84,102
+214% +$11.1M 0.12% 129
2026
Q1 		$5.47M Sell
39,227
-75,412
-66% -$10.6M 0.05% 210
2025
Q4 		$14.1M Buy
114,639
+94,482
+469% +$11.5M 0.15% 83
2025
Q3 		$2.24M Sell
20,157
-9,380
-32% -$1.07M 0.01% 510
2025
Q2 		$3.27M Sell
29,537
-10,638
-26% -$1.13M 0.02% 537
2025
Q1 		$4.5M Buy
+40,175
New +$4.15M 0.04% 154
2024
Q3 		– Sell
-9,435
Closed -$647K – 1249
2024
Q2 		$647K Buy
+9,435
New +$630K 0.01% 524

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's GILD Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Gilead Sciences (GILD) stake by 214% in Q2 2026, buying an estimated $11.1M and bringing the position to 123,329 shares worth $15.6M. The position accounts for 0.12% of the portfolio, ranked #129.

Brevan Howard Capital Management first reported a position in GILD in Q2 2024 and has held it in 7 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Brevan Howard Capital Management held 123,329 shares of Gilead Sciences worth $15.6M as of Q2 2026.
  • Brevan Howard Capital Management bought 84,102 Gilead Sciences shares in Q2 2026, an estimated $11.1M.
  • Gilead Sciences made up 0.12% of Brevan Howard Capital Management's portfolio in Q2 2026, its #129 holding.
  • Brevan Howard Capital Management first reported a position in Gilead Sciences in Q2 2024 and has held it in 7 quarters since.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.